ZAVEDOS (idarubicin), anthracycline

No clinical added value demonstrated in comparison with daunorubicin in induction therapy for newly diagnosed acute myeloid leukaemia in children

• ZAVEDOS, in combination with cytarabine, now has marketing authorisation in the 1^st-line setting for remission induction in previously untreated children with acute myeloid leukaemia (AML).
• As in adults, anthracyclines play a key role in chemotherapy regimens, particularly induction for AML.
• In the context of induction regimens, intravenous idarubicin is an alternative to daunorubicin in the treatment of previously untreated childhood AML.